BioLight Life (Israel) Buy Hold or Sell Recommendation

    BOLT -- Israel Stock  

    ILS 1,520  17.00  1.13%

    Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding BioLight Life Sciences Ltd is 'Not Rated'. Macroaxis provides BioLight Life buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BOLT positions. The advice algorithm takes into account all of BioLight Life Sciences available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BOLT buy-and-hold prospective. Check also Trending Equities.

    Time Horizon

    Risk Tolerance

    Execute Advice
    Sell BioLight LifeBuy BioLight Life
    Not Rated
    For the selected time horizon BioLight Life Sciences Ltd has a risk adjusted performance of 0.2798, jensen alpha of 0.4478, total risk alpha of 0.6071, sortino ratio of 0.4257 and treynor ratio of 0.71
    Macroaxis provides buy, hold, or sell suggestion on BioLight Life Sciences to complement and cross-verify current analyst consensus on BioLight Life Sciences Ltd. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure BioLight Life is not overpriced, please confirm all BioLight Life Sciences fundamentals including its Price to Book, Revenue, EBITDA, as well as the relationship between Price to Sales and Gross Profit .

    BioLight Life Returns Distribution Density

    Mean Return0.50Value At Risk1.64
    Potential Upside5.86Standard Deviation1.97
     Return Density 

    BioLight Life Alerts

    Trading Alerts and Improvement Suggestions

    BioLight Life is not yet fully synchronised with the market data
    The company reported revenue of 4.16 M. Net Loss for the year was (13.8 M) with profit before overhead, payroll, taxes, and interest of 450 K.
    BIO LIGHT ISR LFE has accumulated about 39.18 M in cash with (25.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.4.

    Latest Analysts View

    BioLight Life Current Analysts Recommendations

    Target Median Price12.00
    Target Mean Price12.00
    Target High Price12.00
    Number Of Analyst Opinions1
    Target Low Price12.00
    Check also Trending Equities. Please also try CEO Directory module to screen ceos from public companies around the world.